• NET Formation in CML: PAD4 Activity and Tyrosine Kinase Inhi

  2026-04-28

  This study reveals that neutrophil extracellular traps (NETs) are elevated in chronic myeloid leukemia (CML) and that tyrosine kinase inhibitors (TKIs), particularly ponatinib, differentially affect NET formation. The research highlights the central role of PAD4-mediated histone citrullination in NETosis, providing a mechanistic link between CML, TKI therapy, and vascular complications.

• JSH-23 as a Precision Tool for NF-κB–Inflammasome Axis Disse

  2026-04-28

  Discover how JSH-23, a potent NF-κB inhibitor, enables advanced inflammation research by uniquely probing the NF-κB–NLRP3 inflammasome axis. This article delivers fresh insight for scientists seeking rigorous, pathway-selective control.

• Cyclic Pifithrin-α Hydrobromide: Precision p53 Inhibition in

  2026-04-27

  Cyclic Pifithrin-α hydrobromide empowers researchers to dissect p53-driven apoptosis and DNA damage responses with exceptional selectivity. Its robust performance in both cancer and neuroinflammatory models enables reliable workflow optimization, especially when reproducibility and targeted pathway modulation are critical.

• iPSC-Based Drug Prescreening for Ultrare Disease Clinical Tr

  2026-04-27

  Sequiera et al. developed a patient-specific iPSC-based platform to prescreen drug efficacy and safety for individuals with ultrarare Leigh-like syndrome mutations. This approach demonstrates how personalized stem cell models can inform clinical trial selection and help guide therapies in rare genetic diseases.

• Cefiderocol’s In Vitro Efficacy Against Resistant Gram-Negat

  2026-04-26

  This study provides the most comprehensive in vitro assessment to date of cefiderocol activity against European Pseudomonas aeruginosa and Acinetobacter species, including strains resistant to meropenem and modern β-lactam/β-lactamase inhibitor combinations. Its findings inform antibiotic selection protocols and advance understanding of resistance mechanisms in high-priority Gram-negative pathogens.

• Demethyleneberberine: Mechanistic Insights in Neurodegenerat

  2026-04-25

  This review centers on the mechanistic potential of Demethyleneberberine (DMB) as a neuroprotective agent in neurodegenerative disorders. The referenced work systematically dissects how DMB modulates pathways implicated in neuronal loss, highlighting its multi-pathway activity and translational relevance for disease modeling.

• Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagon

  2026-04-24

  Dantrolene sodium salt, a calmodulin-dependent ryanodine receptor antagonist, enables precise modulation of intracellular calcium signaling for advanced disease modeling and genome editing workflows. Explore protocol optimization, troubleshooting tactics, and experimental innovations that set this compound apart for translational research applications.

• Veratridine (SKU B7219): Reliable Sodium Channel Dynamics Re

  2026-04-24

  Explore how Veratridine (SKU B7219) from APExBIO solves key laboratory challenges in sodium channel dynamics research. This article covers reproducibility, protocol optimization, and data interpretation for cell-based assays, empowering biomedical researchers with scenario-driven, evidence-backed guidance.

• RG7388 MDM2 Antagonist: Workflow Precision in p53 Pathway Ac

  2026-04-23

  RG7388 empowers researchers to achieve precision p53 pathway activation and reliable cancer cell apoptosis induction, outperforming earlier MDM2 antagonists. This guide distills experimental best practices, troubleshooting strategies, and cutting-edge protocol enhancements for robust preclinical and translational oncology workflows.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-23

  Schwartz's dissertation introduces a nuanced framework for distinguishing between proliferative arrest and cell death when assessing anti-cancer drug efficacy in vitro. This work advances experimental rigor in cancer biology by clarifying measurement strategies and highlights implications for interpreting angiogenesis inhibitor studies.

• Harnessing Angiotensin II for Translational Vascular Researc

  2026-04-22

  This thought-leadership article illuminates the mechanistic depth and translational breadth of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) as a potent vasopressor and GPCR agonist. It synthesizes recent advances in vascular smooth muscle cell hypertrophy research, hypertension mechanism study, and cardiovascular remodeling investigation. By critically appraising the product's competitive landscape and embedding strategic protocol guidance, it equips translational scientists to drive innovation with APExBIO’s gold-standard Angiotensin II reagent.

• Phosphatase Inhibitor Cocktail 2: Precision in Phosphorylati

  2026-04-22

  Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) from APExBIO delivers robust, validated inhibition for both tyrosine and serine/threonine phosphatases, securing reliable protein phosphorylation profiles in cellular extracts. This article details optimized protocols, practical troubleshooting, and advanced applications that set this cocktail apart in high-fidelity signaling and metabolic research.

• Pharmacokinetic Variability of CSBTA in MASH: Tissue and Sys

  2026-04-21

  This study systematically characterizes how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mouse models. The findings demonstrate that disease-induced changes in metabolic enzymes and transporters substantially modulate systemic exposure and hepatic accumulation of key alkaloids, providing a foundation for rationalizing therapeutic dosing in MASH.

• Mitomycin C: Antitumor Antibiotic Workflows in Cancer Resear

  2026-04-21

  Mitomycin C, a gold-standard antitumor antibiotic, empowers reproducible apoptosis signaling research and advanced cancer models. This guide delivers protocol-driven insights, evidence-backed troubleshooting, and actionable strategies to maximize experimental impact using APExBIO’s trusted reagent.

• Targeting PCNA-POLD1 Axis Prevents Pathologic Heart Hypertro

  2026-04-20

  Pal et al. uncover that cardiomyocyte hypertrophy is driven by PCNA-POLD1–mediated DNA synthesis and endoreplication, with p21 acting as a negative regulator. Their work demonstrates that genetic or viral targeting of this pathway can prevent maladaptive cardiac remodeling and improve ventricular function, providing new mechanistic insights and potential translational strategies.

450 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page